Novavax Inc Dossier
Qualitative Analysis
Business overview
Novavax, Inc. (Nasdaq: NVAX) is a late-stage biotechnology company historically known for developing and commercializing recombinant nanoparticle vaccines, such as its protein-based COVID-19 vaccine Nuvaxovid™. In response to a rapidly declining seasonal COVID-19 vaccine market, the company is executing a major strategic pivot. Novavax is transitioning from a direct vaccine manufacturer and commercializer to a technology licensing and partnership model. This model leverages its proprietary Matrix-M® adjuvant technology and other R&D assets. Key milestones in this transition include a major co-exclusive licensing agreement with Sanofi and a non-exclusive Matrix-M license with Pfizer.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Pivoting from direct commercialization of COVID-19 vaccines to a high-margin, partner-led licensing and royalty model. Lead commercial responsibility for Nuvaxovid has been transitioned to Sanofi starting with the 2025-2026 vaccination season.
Expected impact: Reduces commercial infrastructure costs, stabilizes cash flows through double-digit royalties, and leverages Sanofi's global commercial scale.
Expanding the licensing of Novavax's proprietary Matrix-M adjuvant technology to global pharmaceutical and biotech companies across infectious disease and oncology vaccine portfolios.
Expected impact: Generates upfront payments, development milestones, and high-mid-single digit percentage royalties on partner vaccine sales.
Executing a multi-year restructuring plan to downsize headcount, consolidate facilities (including Maryland site consolidation), and optimize operating expenses.
Expected impact: Aims to reduce combined R&D and SG&A expenses to $200 million or below by 2028, representing a 50%+ reduction from 2025 levels.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Critical lifeline that transitioned commercialization of Nuvaxovid to Sanofi, allowing Novavax to focus on R&D and platform licensing.
Terms: Provided $500 million upfront in 2024, with $225 million in milestones earned by Novavax in 2025. Includes tiered double-digit royalties on Nuvaxovid sales and potential future milestones (e.g., $125M for Phase 3 CIC initiation, $75M for tech transfer).
Validates the commercial utility of the Matrix-M adjuvant platform in major infectious disease areas.
Terms: Novavax received a $30 million upfront payment in Q1 2026, with potential for up to $500 million in additional development and sales milestones, plus high-mid-single digit percentage royalties on sales.